変形性関節症治療薬の市場規模、シェア、成長分析：薬物タイプ別、解剖学別、投与経路別、販売チャネル別、最終用途別、地域別 - 産業予測 2025～2032年

変形性関節症治療薬市場規模は2023年に95億米ドルと評価され、2024年の101億6,000万米ドルから2032年には173億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.9％で成長する見通しです。

2023年1月のCDCデータによると、変形性関節症に罹患する米国人は3,250万人を超え、市場は大きく成長する見込みです。特に高齢者と女性におけるこの有病率の急増は、効果的な治療に対する重大な需要を裏付けています。筋骨格系の異常やホルモンの変化といった要因が女性のリスク上昇に寄与しており、女性に多い肥満がさらにこの疾患の素因となっています。この分野の研究開発が強化されるにつれ、特に関節内薬物投与や疾患修飾薬による革新的な治療ソリューションが出現しつつあります。こうした進歩や変形性関節症に対するより深い理解によって市場の拡大が予想される中、この重大な健康課題に対処するための的を絞った介入には、明確な機会があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

変形性関節症治療薬市場規模：薬物タイプ別& CAGR（2025-2032）

• 市場概要
• 関節内補充療法剤
• 非ステロイド性抗炎症薬
  • ナプロキセン
  • アスピリン
  • ジクロフェナク
  • イブプロフェン
  • セレコキシブ
  • メロキシカム
  • ピロキシカム
  • ケトプロフェン
  • その他のNSAID
• 鎮痛剤
  • デュロキセチン
  • アセトアミノフェン
• コルチコステロイド
• その他

変形性関節症治療薬市場規模：解剖学別& CAGR（2025-2032）

• 市場概要
• 変形性膝関節症
• 変形性股関節症
• 手の変形性関節症
• その他

変形性関節症治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 非経口投与
  • ヒアルロン酸注射
  • コルチコステロイド注射
  • 多血小板血漿（PRP）注射
  • 胎盤組織マトリックス（PTM）注射
  • アセチルサリチル酸（ASA）注射
  • その他
• 局所経路
• 経口投与

変形性関節症治療薬市場規模：販売チャネル別& CAGR（2025-2032）

• 市場概要
• 処方薬
• 市販薬

変形性関節症治療薬市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• その他

変形性関節症治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Sanofi S.A.（France）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Flexion Therapeutics, Inc.（USA）
• Seikagaku Corporation（Japan）
• TissueGene, Inc.（South Korea）
• Anika Therapeutics, Inc.（USA）
• Ampio Pharmaceuticals, Inc.（USA）
• BioDelivery Sciences International, Inc.（USA）
• Bone Therapeutics SA（Belgium）
• Kolon TissueGene, Inc.（South Korea）
• Centrexion Therapeutics Corporation（USA）
• Kiniksa Pharmaceuticals, Ltd.（Bermuda）

結論と提言

Osteoarthritis Therapeutics Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The osteoarthritis market is poised for significant growth, with over 32.5 million Americans affected, according to January 2023 CDC data. This surge in prevalence, particularly among older adults and women, underscores the critical demand for effective therapies. Factors such as musculoskeletal abnormalities and hormonal changes contribute to the heightened risk in women, while obesity, which is more common among females, further predisposes them to the condition. As research and development in this area intensify, innovative treatment solutions, particularly through intra-articular drug administration and disease-modifying medications, are emerging. With the market expected to expand due to these advancements and a deeper understanding of osteoarthritis, there's a clear opportunity for targeted interventions that address this significant health challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The global osteoarthritis therapeutics market is poised for significant growth, particularly within the rapidly aging populations in developed regions like North America and Europe. As the number of elderly individuals rises, the prevalence of joint degenerative diseases also increases, leading to a greater need for effective treatment options. This surge in demand not only propels market growth but also fosters innovation within the therapeutic landscape, as pharmaceutical companies and researchers strive to develop novel and improved solutions for osteoarthritis management. Consequently, the combination of demographic trends and the corresponding healthcare needs creates a robust environment for market expansion.

Restraints in the Osteoarthritis Therapeutics Market

A significant restraint in the Osteoarthritis Therapeutics market stems from the potential side effects linked to traditional treatments like NSAIDs and corticosteroids. The extended use of these medications can result in serious complications, including gastrointestinal disorders and cardiovascular diseases. This adverse effect profile makes patients hesitant to rely on these conventional therapies, prompting them to explore alternative options instead. Consequently, the undesirable nature of these drugs hampers their widespread acceptance and limits their usage in the mainstream treatment of osteoarthritis, ultimately impacting market growth and development. As patients prioritize safety, the demand for safer, more effective alternatives continues to rise.

Market Trends of the Osteoarthritis Therapeutics Market

The Osteoarthritis Therapeutics market is witnessing a notable trend towards the rising adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These innovative therapies offer effective pain relief and enhance joint function while significantly minimizing recovery times compared to traditional surgical interventions. As patients increasingly seek alternatives that allow for quicker return to daily activities, and as healthcare providers recognize the benefits of these less invasive options, the demand for minimally invasive solutions in osteoarthritis management is expected to grow. This shift not only improves patient satisfaction but also reflects an evolving landscape in arthritis care that prioritizes efficiency and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Viscosupplementation Agents
• Nonsteroidal Anti-inflammatory Drugs
  • Naproxen
  • Aspirin
  • Diclofenac
  • Ibuprofen
  • Celecoxib
  • Meloxicam
  • Piroxicam
  • Ketoprofen
  • Other NSAIDs
• Analgesics
  • Duloxetine
  • Acetaminophen
• Corticosteroids
• Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2025-2032)

• Market Overview
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Parenteral Route
  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet-rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) Injections
  • Acetylsalicylic Acid (ASA) Injections
  • Others
• Topical Route
• Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • US
  • Canada
• Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDelivery Sciences International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bone Therapeutics SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals, Ltd. (Bermuda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations